Active, not recruitingPhase 3NCT04161898

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

Studying Takayasu arteritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AbbVie
Principal Investigator
ABBVIE INC.
AbbVie
Intervention
Upadacitinib(drug)
Enrollment
56 enrolled
Eligibility
15 years · All sexes
Timeline
20202028

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04161898 on ClinicalTrials.gov

Other trials for Takayasu arteritis

Additional recruiting or active studies for the same condition.

See all trials for Takayasu arteritis

← Back to all trials